MEI Pharma Reports Preliminary Data From Phase II Study On Pracinostat

(RTTNews) - MEI Pharma, Inc. (MEIP) announced preliminary response data from the first stage of a two-stage, open-label Phase II clinical study of its investigational drug candidate Pracinostat in combination with Vidaza (azacitidine) in elderly patients with newly diagnosed acute myeloid leukemia who are unsuitable for intensive chemotherapy.

Of the first nine patients enrolled in the study, two achieved a complete response (CR) and one achieved a complete response with incomplete blood count recovery (CRi), each following one or two treatment cycles, the company reported. The data met the pre-specified CR/CRi rate required to advance to the second stage of the study. In addition, three patients achieved a partial response or a partial response with incomplete blood count recovery after their initial or second treatment evaluation, for an overall response rate of 67%.

The combination of Pracinostat and Vidaza has been generally well tolerated in the study, the company said.